

Product Name: JAK2 Rabbit Polyclonal Antibody

Catalog #: APRab12820

For research use only.

Summary

Description Rabbit polyclonal Antibody

Host Rabbit

Application WB,IHC,ICC/IF,ELISA
Reactivity Human,Mouse,Rat
Conjugation Unconjugated
Modification Unmodified

Isotype IgG

Clonality Polyclonal
Form Liquid
Concentration 1mg/ml

Storage Aliquot and store at -20°C (valid for 12 months). Avoid freeze/thaw cycles.

Shipping Ice bags

Liquid in PBS containing 50% glycerol, 0.5% protective protein and 0.02% New type **Buffer**

preservative N.

Purification Affinity purification

Application

Dilution Ratio WB 1:500-1:2000,IHC 1:100-1:300,ICC/IF 1:50-1:200,ELISA 1:5000-1:20000

Molecular Weight 130kDa

Antigen Information

Gene Name JAK2

Alternative Names JAK2; Tyrosine-protein kinase JAK2; Janus kinase 2; JAK-2

 Gene ID
 3717.0

 SwissProt ID
 060674

The antiserum was produced against synthesized peptide derived from human JAK2. AA **Immunogen**

range:981-1030

Background

This gene product is a protein tyrosine kinase involved in a specific subset of cytokine receptor signaling pathways. It has been



found to be constituitively associated with the prolactin receptor and is required for responses to gamma interferon. Mice that do not express an active protein for this gene exhibit embryonic lethality associated with the absence of definitive erythropoiesis. [provided by RefSeq, Jul 2008],catalytic activity:ATP + a [protein]-L-tyrosine = ADP + a [protein]-L-tyrosine phosphate, disease: Chromosomal aberrations involving JAK2 are found in both chronic and acute forms of eosinophilic, lymphoblastic and myeloid leukemia. Translocation t(8;9)(p22;p24) with PCM1 links the protein kinase domain of JAK2 to the major portion of PCM1. Translocation t(9;12)(p24;p13) with ETV6., disease: Defects in JAK2 are a cause of acute myelogenous leukemia (AML) [MIM:601626]. AML is a malignant disease in which hematopoietic precursors are arrested in an early stage of development., disease: Defects in JAK2 are a cause of susceptibility to Budd-Chiari syndrome [MIM:600880]. Budd-Chiari syndrome is a spectrum of disease states, including anatomic abnormalities and hypercoagulable disorders, resulting in hepatic venous outflow occlusion. Clinical manifestations observed in the majority of patients include hepatomegaly, right upper quadrant pain, and abdominal ascites., disease: Defects in JAK2 are associated with familial myelofibrosis [MIM:254450]. Myelofibrosis with myeloid metaplasia is a myeloproliferative disease with annual incidence of 0.5-1.5 cases per 100,000 individuals and age at diagnosis around 60 (an increased prevalence is noted in Ashkenazi Jews). Clinical manifestations depend on the type of blood cell affected and may include anemia, pallor, splenomegaly, hypermetabolic state, petechiae, ecchymosis, bleeding, lymphadenopathy, hepatomegaly, portal hypertension., disease: Defects in JAK2 are associated with polycythemia vera (PV) [MIM:263300]. PV, the most common form of primary polycythemia, is caused by somatic mutation in a single hematopoietic stem cell leading to clonal hematopoiesis. PV is a myeloproliferative disorder characterized predominantly by erythroid hyperplasia, but also by myeloid leukocytosis, thrombocytosis, and splenomegaly. Familial cases of PV are very rare and usually manifest in elderly patients, disease: Defects in JAK2 gene may be a cause of essential thrombocythemia (ET) [MIM:187950]. ET is characterized by elevated platelet levels due to sustained proliferation of megakaryocytes, and frequently lead to thrombotic and haemorrhagic complications.,domain:Possesses two phosphotransferase domains. The second one probably contains the catalytic domain (By similarity), while the presence of slight differences suggest a different role for domain 1, function: Plays a role in leptin signaling and control of body weight (By similarity). Tyrosine kinase of the non-receptor type, involved in interleukin-3 and probably interleukin-23 signal transduction, PTM: Leptin promotes phosphorylation on tyrosine residues, including phosphorylation on Tyr-813., similarity: Belongs to the protein kinase superfamily. Tyr protein kinase family, similarity: Belongs to the protein kinase superfamily. Tyr protein kinase family. JAK subfamily., similarity: Contains 1 FERM domain., similarity: Contains 1 protein kinase domain., similarity: Contains SH₂ domain.,subcellular location:Wholly intracellular, possibly membrane associated.,subunit:Interacts with SIRPA and SH2B1 (By similarity). Interacts with IL23R, SKB1 and STAM2.,tissue specificity: Expressed in blood, bone marrow and lymph node.,


Research Area

Chemokine; Jak STAT; Adipocytokine;


Image Data

Web: https://www.enkilife.com E-mail: order@enkilife.com techsupport@enkilife.com Tel: 0086-27-87002838







Immunohistochemistry analysis of paraffin-embedded human breast carcinoma tissue, using JAK2 Antibody. The picture on the right is blocked with the synthesized peptide.




Western blot analysis of lysates from HT-29 cells, using JAK2 Antibody. The lane on the right is blocked with the synthesized peptide.




Immunofluorescence analysis of rat-lung tissue. 1,JAK2 Polyclonal Antibody (red) was diluted at 1:200 (4°C,overnight) . 2, Cy3 labled Secondary antibody was diluted at 1:300 (room temperature, 50min) .3, Picture B: DAPI (blue) 10min. Picture A:Target. Picture B: DAPI. Picture C: merge of A+B




Immunofluorescence analysis of rat-spleen tissue. 1,JAK2 Polyclonal Antibody (red) was diluted at 1:200 (4°C,overnight) . 2, Cy3 labled Secondary antibody was diluted at 1:300 (room temperature, 50min) .3, Picture B: DAPI (blue) 10min. Picture A:Target. Picture B: DAPI. Picture C: merge of A+B



Immunohistochemical analysis of paraffin-embedded Human-uterus tissue. 1,JAK2 Polyclonal Antibody was diluted at 1:200 (4°C,overnight) . 2, Sodium citrate pH 6.0 was used for antibody retrieval (>98°C,20min) . 3,Secondary antibody was diluted at 1:200 (room tempeRature, 30min) . Negative control was used by secondary antibody only.




Immunohistochemical analysis of paraffin-embedded Rat-kidney tissue. 1,JAK2 Polyclonal Antibody was diluted at 1:200 (4°C,overnight) . 2, Sodium citrate pH 6.0 was used for antibody retrieval (>98°C,20min) . 3,Secondary antibody was diluted at 1:200 (room tempeRature, 30min) . Negative control was used by secondary antibody only.




Immunohistochemical analysis of paraffin-embedded Mouse-lung tissue. 1,JAK2 Polyclonal Antibody was diluted at 1:200 (4°C,overnight) . 2, Sodium citrate pH 6.0 was used for antibody retrieval (>98°C,20min) . 3,Secondary antibody was diluted at 1:200 (room tempeRature, 30min) . Negative control was used by secondary antibody only.





Western Blot analysis of various cells using JAK2 Polyclonal Antibody diluted at 1: 2000



Western Blot analysis of HT29 cells using JAK2 Polyclonal Antibody diluted at 1: 2000